Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 21,712 $ 28,918
Prepaid expenses and other current assets 1,298 593
Total Current Assets 23,010 29,511
Property and equipment, net 485 607
Right of Use Asset 481 0
Deposits and other assets 23 23
Total Assets 23,999 30,141
Current Liabilities:    
Accounts payable 1,523 1,034
Accrued expenses 1,544 919
Accrued employee benefits 511 1,332
Deferred rent 0 99
Lease liability 233 0
Total Current Liabilities 3,811 3,384
Long term deferred rent 0 302
Lease liability - Long term 601 0
Total Liabilities 4,412 3,686
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,419 12,296
Stockholders' Equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,647,888, issued and 16,645,560 outstanding and 15,484,411, issued and 15,482,083 outstanding 17 15
Additional paid-in capital 232,211 230,754
Accumulated deficit (227,141) (219,461)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 10,022 17,068
Non-controlling interest (2,854) (2,909)
Total Stockholders' Equity 7,168 14,159
Total Liabilities and Stockholders' Equity 23,999 30,141
Series B Preferred Stock [Member]    
Stockholders' Equity:    
Series B Convertible Preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,823 issued and outstanding and 9,161 issued and outstanding 4,935 5,760
Total Stockholders' Equity $ 4,935 $ 5,760